Published in Ann Thorac Surg on November 01, 2004
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med (2008) 9.40
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest (2006) 4.51
Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation (2002) 3.98
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med (2015) 3.11
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 2.76
Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol (2010) 2.54
New markers of inflammation and endothelial cell activation: Part I. Circulation (2003) 2.43
Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg (2002) 2.31
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 2.16
Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation (2003) 2.03
Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation (2010) 2.02
Microplegia during coronary artery bypass grafting was associated with less low cardiac output syndrome: a propensity-matched comparison. Ann Thorac Surg (2013) 2.00
Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg (2003) 1.96
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation (2002) 1.94
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation (2004) 1.94
Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC Cardiovasc Imaging (2009) 1.94
Endothelial progenitor cells: new hope for a broken heart. Circulation (2003) 1.93
Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg (2005) 1.66
Long-term benefit of postconditioning. Circulation (2008) 1.65
C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation (2004) 1.65
Histologic changes of nonbiodegradable and biodegradable biomaterials used to repair right ventricular heart defects in rats. J Thorac Cardiovasc Surg (2002) 1.64
Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol (2013) 1.59
An adult uterine hemangioblast: evidence for extramedullary self-renewal and clonal bilineage potential. Blood (2010) 1.56
Glitazones and heart failure: critical appraisal for the clinician. Circulation (2003) 1.53
Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg (2007) 1.50
Fundamentals of reperfusion injury for the clinical cardiologist. Circulation (2002) 1.49
The insulin cardioplegia trial: myocardial protection for urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg (2002) 1.48
Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg (2007) 1.48
Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts. Circulation (2002) 1.45
Cardiac restoration: frontier or fantasy? Can J Cardiol (2005) 1.44
Aged human cells rejuvenated by cytokine enhancement of biomaterials for surgical ventricular restoration. J Am Coll Cardiol (2012) 1.42
Myometrial cells induce angiogenesis and salvage damaged myocardium. Am J Physiol Heart Circ Physiol (2006) 1.40
Vascular endothelial growth factor receptor upregulation in response to cell-based angiogenic gene therapy. Ann Thorac Surg (2005) 1.38
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant (2008) 1.25
Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res (2006) 1.24
Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. J Thorac Cardiovasc Surg (2002) 1.24
Culture of rat endometrial telocytes. J Cell Mol Med (2012) 1.23
Optimal biomaterial for creation of autologous cardiac grafts. Circulation (2002) 1.22
Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg (2008) 1.21
Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials (2010) 1.19
Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg (2002) 1.18
Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol (2005) 1.18
c-kit dysfunction impairs myocardial healing after infarction. Circulation (2007) 1.17
Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg (2010) 1.15
Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation (2006) 1.14
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation (2008) 1.14
Tracking cardiac engraftment and distribution of implanted bone marrow cells: Comparing intra-aortic, intravenous, and intramyocardial delivery. J Thorac Cardiovasc Surg (2009) 1.12
Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol (2005) 1.11
Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB J (2007) 1.11
Mueller matrix decomposition for polarized light assessment of biological tissues. J Biophotonics (2009) 1.07
Optimizing cardiac cell therapy: from processing to delivery. J Thorac Cardiovasc Surg (2005) 1.07
Relation between aortic cross-clamp time and mortality--not as straightforward as expected. Eur J Cardiothorac Surg (2008) 1.07
Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation (2003) 1.07
Maximizing ventricular function with multimodal cell-based gene therapy. Circulation (2005) 1.06
Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol (2002) 1.06
Quantitative analysis of survival of transplanted smooth muscle cells with real-time polymerase chain reaction. J Thorac Cardiovasc Surg (2005) 1.06
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation (2004) 1.04
Polarization birefringence measurements for characterizing the myocardium, including healthy, infarcted, and stem-cell-regenerated tissues. J Biomed Opt (2010) 1.04
Cardiac remodeling and failure From molecules to man (Part II). Cardiovasc Pathol (2005) 1.03
Improved left ventricular aneurysm repair with bioengineered vascular smooth muscle grafts. Circulation (2003) 1.02
TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol (2007) 1.02
What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as "universal donor cells". J Card Surg (2010) 1.02
Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation (2005) 1.01
Should radial arteries be used routinely for coronary artery bypass grafting? Circulation (2004) 1.01
Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J (2010) 1.00
Regional overexpression of insulin-like growth factor-I and transforming growth factor-beta1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg (2002) 0.99
Cyclosporine protects the heart during aortic valve surgery. Anesthesiology (2014) 0.97
Enhanced cell transplantation: preventing apoptosis increases cell survival and ventricular function. Am J Physiol Heart Circ Physiol (2006) 0.97
Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol (2015) 0.97
Prevention and management of deep sternal wound infection. Semin Thorac Cardiovasc Surg (2004) 0.96
Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function. Circulation (2013) 0.95
Current status of cellular therapy for ischemic heart disease. Ann Thorac Surg (2005) 0.95
Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg (2002) 0.95
Cardiovascular tissue engineering therapy: so near, so far? Ann Thorac Surg (2005) 0.95
Elastin stabilizes an infarct and preserves ventricular function. Circulation (2005) 0.95
C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg (2003) 0.94
Bicuspid aortic valve disease: recent insights in pathophysiology and treatment. Expert Rev Cardiovasc Ther (2005) 0.94
Improvement in cardiac function after bone marrow cell thearpy is associated with an increase in myocardial inflammation. Am J Physiol Heart Circ Physiol (2008) 0.94
Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation. J Cell Mol Med (2012) 0.93
Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials (2010) 0.93
Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol (2007) 0.93
Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation (2008) 0.91
c-Kit function is necessary for in vitro myogenic differentiation of bone marrow hematopoietic cells. Stem Cells (2009) 0.91
Recipient age determines the cardiac functional improvement achieved by skeletal myoblast transplantation. J Am Coll Cardiol (2007) 0.91
Defining conditions for covalent immobilization of angiogenic growth factors onto scaffolds for tissue engineering. J Tissue Eng Regen Med (2010) 0.90
Clinical applicability of preconditioning and postconditioning: the cardiothoracic surgeons's view. Cardiovasc Res (2006) 0.90
Co-culture with cardiomyocytes enhanced the myogenic conversion of mesenchymal stromal cells in a dose-dependent manner. Mol Cell Biochem (2010) 0.90
Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J Thorac Cardiovasc Surg (2009) 0.90
The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res Cardiol (2014) 0.89
Vascular endothelial growth factor transgene expression in cell-transplanted hearts. J Thorac Cardiovasc Surg (2004) 0.89
Surgical ventricular restoration with a cell- and cytokine-seeded biodegradable scaffold. Biomaterials (2010) 0.89
Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. Am Heart J (2007) 0.89
In vitro and in vivo models of cerebral ischemia show discrepancy in therapeutic effects of M2 macrophages. PLoS One (2013) 0.88